Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology care, vascular surgery, weight loss, and women's health. Further, the company offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. It offers diagnostics, in-patient, daycase, and out-patient care services through 40 hospitals and eight clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on SPI shares. Berenberg Bank restated a "buy" rating and issued a GBX 300 ($3.62) target price on shares of Spire Healthcare Group in a research note on Tuesday, July 12th. Barclays reiterated an "overweight" rating and set a GBX 310 ($3.75) price objective on shares of Spire Healthcare Group in a research note on Tuesday, May 31st. Royal Bank of Canada increased their price objective on shares of Spire Healthcare Group from GBX 240 ($2.90) to GBX 260 ($3.14) and gave the stock a "sector perform" rating in a research note on Tuesday, July 19th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Spire Healthcare Group from GBX 347 ($4.19) to GBX 237 ($2.86) and set an "overweight" rating on the stock in a research note on Thursday, June 30th.
Spire Healthcare Group Stock Down 0.2 %
Shares of LON:SPI opened at GBX 242.59 ($2.93) on Monday. Spire Healthcare Group has a 52 week low of GBX 201 ($2.43) and a 52 week high of GBX 256.50 ($3.10). The company has a debt-to-equity ratio of 179.63, a quick ratio of 0.94 and a current ratio of 1.15. The company has a market cap of £979.74 million and a PE ratio of -101.25. The firm has a 50 day simple moving average of GBX 232.81 and a 200 day simple moving average of GBX 229.69.